CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia

EJHaem Pub Date : 2024-12-28 DOI:10.1002/jha2.1076

Rafael Madero-Marroquin, Ryan W. Hunter, Caner Saygin, Hannah Johnston, Adam S. DuVall, Hamed Rahmani Youshanlouei, Clinton Osei, Syed Shah, Wendy Stock, Sandeep Gurbuxani, Anand A. Patel

{"title":"CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia","authors":"Rafael Madero-Marroquin, Ryan W. Hunter, Caner Saygin, Hannah Johnston, Adam S. DuVall, Hamed Rahmani Youshanlouei, Clinton Osei, Syed Shah, Wendy Stock, Sandeep Gurbuxani, Anand A. Patel","doi":"10.1002/jha2.1076","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756963/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.1076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.

Methods

Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).

Results

The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.

Conclusion

Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.

Abstract Image

查看原文本刊更多论文

CD58表达不影响b细胞急性淋巴细胞白血病患者对inotuzumab ozogamicin的反应。

背景：CD58缺失已被描述为对blinatumab和嵌合抗原受体t细胞治疗耐药的机制，作为对t细胞活化反应的调节剂。方法：使用流式细胞术，我们评估了CD58平均荧光强度（MFI）对使用inotuzumab ozogamicin （InO）治疗的b细胞急性淋巴细胞白血病患者实现可测量残留病（MRD）阴性概率的影响。结果：CD58 MFI每增加1000单位，MRD阴性的比值比为1.03。结论：我们的研究结果表明，无论CD58表达强度如何，InO后MRD阴性率都很高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

EJHaem

自引率

0.00%

发文量